Elevated tryptase levels selectively cluster in myeloid neoplasms: A novel diagnostic approach and screen marker in clinical haematology

European Journal of Clinical Investigation

Volumn 39, Issue 10, 2009, Pages 914-923

  Sperr, W R ^a   El Samahi, A ^a   Kundi, M ^a   Girschikofsky, M ^b   Winkler, S ^a   Lutz, D ^b   Endler, G ^a   Rumpold, H ^a   Agis, H ^a   Sillaber, C ^a   Jager U ^a   Valent, P ^a,c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ELISABETHINEN HOSPITAL   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

AML; CML; Leukaemia; MDS; Tryptase

Indexed keywords

TRYPTASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD LEVEL; BONE MARROW TUMOR; CHILD; CONTROLLED STUDY; FEMALE; HELMINTHIASIS; HEMATOLOGY; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SCREENING; SYSTEMIC MASTOCYTOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, MYELOID; MALE; MAST CELLS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; TRYPTASES; YOUNG ADULT;

EID: 70349256069     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02184.x     Document Type: Article

References (34)

1. Ley TJ, Minx PJ, Walter MJ, Ries RE, Sun H, McLellan M et al. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes. Proc Natl Acad Sci USA 2003 100 : 14275 14280.
2. Bullinger L, Valk PJ. Gene expression profiling in acute myeloid leukemia. J Clin Oncol 2005 23 : 6296 6305.
3. Thadikkaran L, Siegenthaler MA, Crettaz D, Queloz PA, Schneider P, Tissot JD. Recent advances in blood-related proteomics. Proteomics 2005 5 : 3019 3034.
4. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica 2007 92 : 744 752.
5. Laczika K, Novak M, Hilgarth B, Mitterbauer M, Mitterbauer G, Scheidel-Petrovic A et al. Competitive CBFbeta/MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion(16): a pilot study. J Clin Oncol 1998 16 : 1519 1525.
6. Spagnolo DV, Ellis DW, Juneja S, Leong AS, Miliauskas J, Norris DL et al. The role of molecular studies in lymphoma diagnosis: a review. Pathology 2004 36 : 19 44.
7. Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001 98 : 2200 2209.
8. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002 128 : 136 141.
9. Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002 43 : 1097 1105.
10. Sperr WR, Mitterbauer M, Mitterbauer G, Kundi M, Jäger U, Lechner K et al. Quantitation of minimal residual disease in acute myeloid leukemia (AML) by tryptase-monitoring identifies a group of patients with a high risk of relapse. Clin Cancer Res 2005 11 : 6536 6543.
11. Schwartz LB, Lewis RA, Austen KF. Tryptase from human pulmonary mast cells. Purification and characterization. J Biol Chem 1981 256 : 11939 11943.
12. Foster B, Schwartz LB, Devouassoux G, Metcalfe DD, Prussin C. Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils. J Allergy Clin Immunol 2002 109 : 287 293.
13. Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987 316 : 1622 1626.
14. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995 96 : 2702 2710.
15. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001 25 : 553 562.
16. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001 25 : 603 625.
17. Valent P, Horny H-P, Li CY, Longley JB, Metcalfe DD, Parwaresch RM et al. Mastocytosis. In : Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumours, Pathology & Genetics, Tumours of Haematopoietic and Lymphoid Tissues. Lyon : IARCPress Lyon 2001. p. 293 302.
18. Samorapoompichit P, Kiener HP, Schernthaner GH, Jordan JH, Agis H, Wimazal F et al. Detection of tryptase in cytoplasmic granules of basophils in patients with chronic myeloid leukemia and other myeloid neoplasms. Blood 2001 98 : 2580 2583.
19. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003 101 : 4660 4666.
20. Tefferi A, Pardanani A, Li CY. Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities? Blood 2003 102 : 3073 3074.
21. Cairoli R, Ripamonti CB, Granata S, Grillo G, Folli D, Nadali G et al. Serum tryptase levels in acute leukemia at diagnosis: correlation with CBF AML. Blood 2005 106 : 206B, 4510.
22. Cairoli R, Ripamonti CB, Granata S, Grillo G, Folli D, Nadali G et al. Serum tryptase levels in AML at diagnosis: a multicenter retrospective study. Blood 2006 108 : 668A, 2358.
23. Schwartz LB, Bradford TR, Rouse C, Irani AM, Rasp G, Van der Zwan JK et al. Development of a new, more sensitive immunoassay for human tryptase: use in systemic anaphylaxis. J Clin Immunol 1994 14 : 190 204.
24. Wimazal F, Walchshofer S, Baghestanian M, Chott A, Sperr WR, Kopp C et al. Detection of mi transcription factor (MITF) mRNA in a case of myelodysplastic syndrome and bone marrow mastocytosis. Wien Klin Wochenschr 1998 110 : 79 88.
25. Min HK, Moxley G, Neale MC, Schwartz LB. Effect of sex and haplotype on plasma tryptase levels in healthy adults. J Allergy Clin Immunol 2004 114 : 48 51.
26. Valent P, Samorapoompichit P, Sperr WR, Horny HP, Lechner K. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 2002 3 : 90 4.
27. Sperr WR, Drach J, Hauswirth AW, Ackermann J, Mitterbauer M, Mitterbauer G et al. Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation. Clin Cancer Res 2005 11 : 6787 6792.
28. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007 31 : 727 736.
29. Wimazal F, Fonatsch C, Thalhammer R, Schwarzinger I, Müllauer L, Sperr WR et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res 2007 31 : 1461 1468.
30. Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007 37 : 435 453.
31. Olano DG, Álvarez-Twose I, Esteban-López MI, Sánchez-Muñoz L, Alonso Díaz de urana MA, Vega A et al. Safety and effectiveness of immunotherapy in patients with indolent systemic mastocytosis presenting with Hymenoptera venom anaphylaxis. J Allergy Clin Immunol 2008 121 : 519 526.
32. Prokocimer M, Polliack A. Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders. Am J Pathol 1981 75 : 34 8.
33. Aichberger KJ, Mayerhofer M, Vales A, Krauth MT, Gleixner KV, Bilban M et al. The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells. Blood 2006 108 : 3538 3547.
34. Agis H, Krauth MT, Böhm A, Mosberger I, Müllauer L, Simonitsch-Klupp I et al. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol 2006 125 : 273 281.